Colonics
About Me
Recent Posts
- Electromagnetic Biomarker Could Minimize Trial-And-Error Prescribing For Depression
- Endocrine Society Releases Clinical Practice Guideline On Pediatric Obesity
- Key Role In Largest US Children's Study To Be Played By UT Health Science Center At Houston
- Scientists identify a molecule that coordinates the movement of cells
- Maryland Stem Cell Commission Issues Requests For Applications
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
Friends
Links
Entry 1 of 389
Last Page | Next Page
6/28/2008
-
Thallion Receives Health Canada Approval To Initiate Phase II Study For TLN-232 In Metastatic Melanoma Patients
|
Thallion Pharmaceuticals Inc. (TSX:TLN) announced it has conventional leave from the Therapeutic stock Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-232 as a regimen for metastatic melanoma in next that have failed at least one prior therapy. The TLN-232 trial is the second Phase II study to be initiated this year from Thallion's oncology pipeline. More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
